SUMMARY A new combined enzyme linked immunoassay (ELISA) was developed to measure both serum placental-like alkaline phosphatase (PLAP) activity (PLAP A) and concentration (PLAP C) in the same microtitre plate using an Imperial Cancer Research Fund monoclonal antibody, designated HI 7E2. PLAP A and PLAP C were determined together with an existing marker, CA125, in 397 serial samples from 87 patients with epithelial ovarian cancer. Retrospective assessment showed the sensitivity to increase from 73% with CA125 alone, to 88% using CA125 and PLAP A, and to 93% with all three markers in 261 samples from the patients with known active disease at the time of sampling. When the results for all 397 samples were included in the analysis, however, the specificity, sensitivity, accuracy and predictive powers of this monoclonal antibody were not sufficiently high to assist in the prospective follow up of patients with ovarian cancer. This was due to a significant number of false positive and false negative results.
Ovarian cancer produces few local symptoms and presents late in most cases; consequently the mortality is high. Attempts to improve the detection of early stage disease have foundered on the lack of a reliable clinical or radiological screening test. In the past five years screening work has focused on the identification of serological tumour markers which could facilitate earlier diagnosis and disease monitoring, a vital step towards improving the survival of these patients. Although numerous tumour markers have been identified to date,' none is specific enough to warrant its use as a primary diagnostic tool, but several have proved useful for monitoring the course of disease.2 Since the publication of the initial report by Bast et al, 3 CA125 has become the accepted test with which other markers are compared.
There has been considerable interest shown recently in the application of placental-like alkaline phosphatase (PLAP) as a marker of epithelial ovarian cancer (EOC). Ectopic expression of PLAP was first discovered in a patient with squamous cell carcinoma of the lung' and has subsequently been found in Accepted for publication 4 August 1988 various malignancies5 including ovarian cancer. Raised serum concentrations of this oncofetal antigen have been found in 44%,5 35%,6 and 40%' of patients with ovarian cancer.
PLAP is normally produced by the syncytiotrophoblast of the placenta and has been detected in sera as early as 9 weeks' gestation, increasing considerably during the second half of pregnancy.8 It is normally undetectable in the sera of healthy subjects and it is this difference between normal adults and patients with cancer which affords it marker potential. Smoking, however, is an established cause of false positive results. 9 Serum PLAP activity (PLAP A) and concentration (PLAP C) were determined in 387 healthy volunteers and 397 serial samples from 87 patients using a novel combined enzyme linked immunoassay (ELISA), developed by modification of two existing separate assays for PLAP A'°and PLAP C. " Serum CA 125 was also determined in all samples and evaluated with PLAP A and PLAP C in the patients with ovarian cancer. Both PLAP A and PLAP C were measured to investigate a recent report" that PLAP A decreased and PLAP C increased simultaneously with progression of disease. (pH were added and incubated for two hours at 37°C. Optical density was measured at 405 nm using a Titertek Multiskan MCC/340 spectrophotometer (Flow Laboratories, Irvine, Scotland) to determine PLAP A. The plates were then washed four times and 100 p1 rabbit anti-human PLAP (Dakopatts, Denmark) at 1/250 dilution in PBS containing 0-5% w/v bovine serum albumin (BSA) were added and incubated for 30 minutes at room temperature. After washing three times in PBS/Tween 20 100 p1 peroxidase-conjugated goat anti-rabbit IgG (Sigma, Poole, Dorset) at 1/1000 dilution in PBS/0-5% BSA were added and incubated for 30 minutes at room temperature. The plates were finally washed three times and incubated at room temperature for 45 minutes 41 with 100 p1 peroxidase substrate: 0-04% w/v ophenylenediamine and 0-012% v/v H202 in 0-15 M citrate-phosphate buffer (pH 5 0) H2SO4 (50 p1 2 5 M) were added to stop the reaction and PLAP concentration determined by measuring optical density at 492 nm using a Titertek Multiskan MCC/340.
All patient samples were scored true or false by correlating the clinical state at the time of sampling with the antigen titre. Presence of disease was defined on clinical, radiological, or surgical grounds (laparotomy). Clinical disease activity was defined temporally as declared disease progression or reactivated disease within six months of assay. From this the sensitivity, specificity, accuracy and predictive values of PLAP were determined, alone and in combination with CA125. DISCRETE PLAP C ASSAY PLAP C was determined separately to show that preincubation with phosphate substrate for the activity assay did not have any deleterious effects on subsequent PLAP C assay performance in the combined assay.
The plates were coated in the same manner as in the combined assay. After the serum incubation step the plates were washed three times and rabbit anti-human PLAP added. The remainder ofthe assay was identical with that of the combined concentration assay.
Results

ASSAY PERFORMANCE
The correlation between the combined and discrete PLAP C assay was high (n = 34, r = 0-97, y = 1-4 x, p < 0.001) (fig 1) , supporting the use of a combined assay.
Based on results from the near term pregnancy serum pool, the between (n = 160) and within (n = 46) assay coefficients of variation were: 16% and 7 5% for PLAP A assay, 8-2% and 3-8% for combined PLAP C assay, and 13% and 4-4% for discrete PLAP C assay, respectively.
CORRELATION BETWEEN PLAP A AND C IN BLOOD DONORS
Using the results from 397 blood donors, PLAP A and C were poorly associated (n = 387, r = 0-56, y = 0-16 x, p < 0-00 1), although still significantly correlated.
PLAP A did not seem to be influenced by smoking in either male or female blood donors (p > 0 05). PLAP C, however, did seem to be increased by smoking in both male and female donors (p < 0-001). Placental-like alkaline phosphatase concentration optical density at L92nm (discrete assay) Table 4 shows the above indices when the combination of all three markers are considered together; A Determination of both PLAP A and C in a combined assay has several advantages over separate assays. These include reduced expense (in particular halved monoclonal antibody costs) and reduced operator time and error due to sampling variation. The correlation between the combined and discrete PLAP C assay was high, supporting the use of the combined assay. The gradient of the slope was greater than I10, however, for which the reasons are unclear. The greater absorbance in the combined assay was not due to residual p-nitrophenyl phosphate substrate, which showed zero absorbance at wavelengths greater than 470 nm. In the combined assay the catalytic reaction may have induced a conformational change in PLAP which results in enhanced recognition and binding by the rabbit anti-human PLAP. The data show that PLAP A and PLAP C assays, individually and in combination, are insufficiently sensitive and specific (tables 2 and 3) for the management of women with epithelial ovarian cancer. Several reasons for the failure of PLAP to fulfil expectations may be postulated. Changes in antigen expression during disease progression and increasing tumour dedifferentiation are complex, substantiated by the lack ofclose correlation we have found between PLAP A and PLAP C in cancer patients when compared with normal controls. These findings contrast with reports from another group who used a different monoclonal antibody raised against PLAP. '4 Numerous factors influence the expression of PLAP, including smoking, which induces PLAP-like alkaline phosphatase synthesis and secretion by lung alveoli.'5 H17E2 recognises this isoenzyme,16 which may in part account for a high proportion of false positive results in our series of patients. Whether a "smoking effect" was a source of error in this series is uncertain. The control sera showed a significant increase in the reference interval only in the PLAP C assay; in the patients' sera many more false positive results were seen with PLAP A than with the PLAP C assay. For PLAP C the use ofa correction factor based on observations in the large control group might reasonably be expected to have reduced the false positive results associated with smoking. Unfortunately, information on the smoking habits in most patients was unobtainable, hence the effect ofsmoking on the patients' PLAP values could not be assessed properly.
PLAP has not previously been evaluated in terms of sensitivity, specificity, accuracy and predictive power, 6 although numerous reports advocate its use as a tumour marker in ovarian cancer." " ' 1 4 When results for PLAP A and PLAP C were combined with CA125 results the overall sensitivity increased from Fisken, Leonard, Shaw, Bowman, Roulston 73% with CA125 alone to 93% with all three markers, where at least one gave a positive result (table 4a) Tucker et al have found determination of PLAP activity using HI 7E2 useful in the follow up of testicular germ cell tumours, particularly seminomas.' The applicability of the simple combined assay deserves to be tested in this and possibly other cancers.
The combined assay, using a more specific monoclonal antibody, one which does not react with PLAP induced by smoking,6 may prove useful in the follow up of patients with ovarian cancer. Increased 'specificity would then be obtained, possibly at the expense of sensitivity-an acceptable modification in the context of a panel of markers where specificity of each marker is the most important criterion.
Although measurement of PLAP was not found to be generally helpful, a few patients may have benefited from additional PLAP assay (fig 2) . It is impossible at this stage to judge which patients will benefit most from prospective serial measurement of PLAP. Appropriate patient selection is essential if PLAP is to be ofuse in future as an adjunct in monitoring ovarian cancer.
Unfortunately, insufficient preoperative samples were available in this study to assess the value ofPLAP
